Literature Review of Fatigue Scales and Association with Clinically Meaningful Improvements in Outcomes Among Patients With and Without Paroxysmal Nocturnal Hemoglobinuria
- PMID: 35316499
- PMCID: PMC9056457
- DOI: 10.1007/s12325-022-02111-7
Literature Review of Fatigue Scales and Association with Clinically Meaningful Improvements in Outcomes Among Patients With and Without Paroxysmal Nocturnal Hemoglobinuria
Abstract
Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder characterized by anemia and debilitating fatigue. Limited evidence characterizes the association between hemoglobin, an indicator of anemia and disease activity, and patient-reported fatigue scales. This review identifies benchmarks for clinically meaningful improvements in patients with and without PNH.
Methods: MEDLINE, Embase, Cochrane, and PsycINFO databases were searched along with Google Scholar to identify publications for patients with and without PNH. Full-text articles and conference abstracts of clinical trials or observational studies that examined patient-reported fatigue or associations between fatigue and hemoglobin were included.
Results: Fourteen publications were included in this study. Four clinical trials conducted in patients with PNH reported that patients achieved and sustained clinically meaningful improvements in fatigue. However, these studies did not examine the association between fatigue and hemoglobin. Ten studies conducted in patients with cancer and anemia (with or without chemotherapy) demonstrated an association between increased hemoglobin and improvements in fatigue (P < 0.05). The greatest incremental gain in fatigue improvement was observed when hemoglobin increased from 11 to 12 g/dL.
Conclusion: Evidence among patients with cancer without PNH demonstrates that increased hemoglobin levels are associated with clinically significant improvements in fatigue. Future studies should validate this relationship among patients with PNH.
Keywords: Fatigue; Hemoglobin; PNH; Paroxysmal nocturnal hemoglobinuria; Quality of life.
© 2022. The Author(s).
Figures
Similar articles
-
Clinically important change for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data.J Patient Rep Outcomes. 2023 Jul 5;7(1):63. doi: 10.1186/s41687-023-00609-4. J Patient Rep Outcomes. 2023. PMID: 37405515 Free PMC article.
-
Burden of illness in Japanese patients with paroxysmal nocturnal hemoglobinuria receiving C5 inhibitors.Int J Hematol. 2024 Mar;119(3):255-264. doi: 10.1007/s12185-023-03698-5. Epub 2024 Jan 19. Int J Hematol. 2024. PMID: 38243016 Free PMC article.
-
Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study.Ann Hematol. 2022 Sep;101(9):1905-1914. doi: 10.1007/s00277-022-04887-8. Epub 2022 Jul 23. Ann Hematol. 2022. PMID: 35869984 Free PMC article. Clinical Trial.
-
Relationship between aplastic anemia and paroxysmal nocturnal hemoglobinuria.Int J Hematol. 2002 Feb;75(2):117-22. doi: 10.1007/BF02982015. Int J Hematol. 2002. PMID: 11939256 Review.
-
Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis.Ther Adv Hematol. 2023 Dec 14;14:20406207231216080. doi: 10.1177/20406207231216080. eCollection 2023. Ther Adv Hematol. 2023. PMID: 38105771 Free PMC article. Review.
Cited by
-
Microbiota and mycobiota in bronchoalveolar lavage fluid of silicosis patients.J Occup Med Toxicol. 2023 Jul 10;18(1):10. doi: 10.1186/s12995-023-00377-3. J Occup Med Toxicol. 2023. PMID: 37430310 Free PMC article.
-
Novel insights into athlete physical recovery concerning lactate metabolism, lactate clearance and fatigue monitoring: A comprehensive review.Front Physiol. 2025 Mar 25;16:1459717. doi: 10.3389/fphys.2025.1459717. eCollection 2025. Front Physiol. 2025. PMID: 40200988 Free PMC article. Review.
-
Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies.Blood Adv. 2025 Apr 22;9(8):1816-1826. doi: 10.1182/bloodadvances.2024014652. Blood Adv. 2025. PMID: 39774762 Free PMC article. Clinical Trial.
References
-
- Jalbert JJ, Chaudhari U, Zhang H, Weyne J, Shammo JM. Epidemiology of PNH and real-world treatment patterns following an incident PNH diagnosis in the US. Blood. 2019;134(Supplement_1):3407. doi: 10.1182/blood-2019-125867. - DOI
-
- Hill A, Platts PJ, Smith A, et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire. Blood. 2006;108(11):985. doi: 10.1182/blood.V108.11.985.985. - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources